Cargando…

Use of CD200 blockade inhibitor to enhance glioma immunotherapy

Detalles Bibliográficos
Autores principales:	Mesias, Elisabet, Xiong, Zhengming, Pluhar, Elizabeth, Olin, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646113/ http://dx.doi.org/10.1186/2051-1426-3-S2-P38

Ejemplares similares

Treatment Combining CD200 Immune Checkpoint Inhibitor and Tumor-Lysate Vaccination after Surgery for Pet Dogs with High-Grade Glioma
por: Olin, Michael R., et al.
Publicado: (2019)

CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy
por: Moertel, Christopher L, et al.
Publicado: (2014)

IMMU-10. USE OF A SINGLE PEPTIDE CHECKPOINT INHIBITOR FOR TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS
por: Moertel, Christopher, et al.
Publicado: (2021)

Understanding and overcoming the immunosuppressive effects of glioma induced immunosuppression
por: Moertel, Christopher, et al.
Publicado: (2013)

Antibody blockade of semaphorin 4D breaks down barriers to enhance tumoricidal immune infiltration and supports rational immunotherapy combinations
por: Evans, Elizabeth E, et al.
Publicado: (2015)

Combined radiotherapy and immunotherapy using CPG oligodeoxynucleotides and indolamine 2,3 dioxygenase (IDO) blockade
por: Monjazeb, Arta M, et al.
Publicado: (2013)

Interaction between effector and memory cd8+ t cells enhances melanoma adoptive immunotherapy
por: Contreras, Amanda, et al.
Publicado: (2015)

TRLS-09. USE OF A PAN-PEPTIDE CHECKPOINT INHIBITOR IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS
por: Moertel, Christopher, et al.
Publicado: (2023)

Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade
por: Choe, Deborah, et al.
Publicado: (2023)

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
por: Broucek, Joseph R, et al.
Publicado: (2013)

P16-08. Combined blockade of the PD-1 and IL-10 pathways synergistically enhance HIV-specific CD4 T cell functions
por: Porichis, F, et al.
Publicado: (2009)

Adoptive immunotherapy for AML with CD123-engager T cells
por: Bonifant, Challice, et al.
Publicado: (2015)

Induction of potent systemic anti-melanoma immunity through intratumoral CD40 activation and checkpoint blockade
por: Singh, Manisha, et al.
Publicado: (2015)

Antibody-mediated blockade of phosphatidylserine enhances the anti-tumor activity of targeted therapy and immune checkpoint inhibitors by affecting myeloid and lymphocyte populations in the tumor microenvironment
por: Yopp, Adam, et al.
Publicado: (2014)

Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade
por: Mueller, Antonia MS, et al.
Publicado: (2014)

Tumor-induced suppressive CD8+ T cells: implications for cancer immunotherapy
por: Pfannenstiel, Lukas W, et al.
Publicado: (2013)

PD-1 blockade reverses viral infection-induced loss of anti-tumor CD8+ T cell responses
por: Huelsmann, Erica, et al.
Publicado: (2013)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)

ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
por: Mangsbo, Sara M, et al.
Publicado: (2013)

RNAi-mediated knockdown of Dnmt3a enhances antibody titer in CHO cells up to 200 percent
por: Schmidt, Anica, et al.
Publicado: (2015)

P710: MONOCYTES MEDIATE NK CELL FUNCTION EXHAUSTION IN MDS PATIENTS VIA CD200/CD200R PATHWAY
por: Guo, Yixuan, et al.
Publicado: (2023)

T lymphocyte engineering with cytokine nanogels for enhanced cancer immunotherapy
por: Tang, Li, et al.
Publicado: (2015)

Enhanced anti-tumor effects of the PD-1/PD-L1 blockade by combining a highly absorptive form of NF-kB/STAT3 inhibitor curcumin
por: Hayakawa, Taeko, et al.
Publicado: (2014)

Selinexor, a selective inhibitor of nuclear export (SINE), shows enhanced activity in combination with PD-1/PD-L1 blockade in syngeneic murine models of colon cancer and melanoma
por: Farren, Matthew R, et al.
Publicado: (2015)

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV-negative volunteers
por: Jackson, AGA, et al.
Publicado: (2010)

Purine nucleoside phosphorylase inhibitors - an immunotherapy with novel mechanism of action for the treatment of melanoma
por: Bantia, Shanta
Publicado: (2015)

Preclinical to clinical translation of anti-PD-1 blockade
por: Hirsch, Heather, et al.
Publicado: (2015)

MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction
por: Irving, Bryan A, et al.
Publicado: (2013)

Cell-selective oligonucleotide STAT3 inhibitor for immunotherapy of human acute myeloid leukemia
por: Zhang, Qifang, et al.
Publicado: (2015)

Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation
por: Minev, Boris, et al.
Publicado: (2014)

Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of downstream immune checkpoint inhibition in K1735 mouse melanoma
por: Huang, Xianming, et al.
Publicado: (2014)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015)

Various inflammatory phenotypes in V200M NLRP3 carriers
por: Kozlova, A, et al.
Publicado: (2015)

Combination OX40 agonism/CTLA-4 blockade with vaccination reverses anergy and primes tumor-specific CD8 T cells in mice with spontaneous prostate cancer
por: Linch, Stefanie N, et al.
Publicado: (2013)

Hip arthritis in the TNF-Blockade era: an unresolved issue?
por: Scott, C, et al.
Publicado: (2008)

Potent ex vivo expanded, human CD34+ cord blood-derived natural killer cells for cancer immunotherapy
por: Zhang, Xiaokui, et al.
Publicado: (2015)

Characterization and performance of the Allegro™ STR 200 single-use stirred tank bioreactor
por: Rees, Byron, et al.
Publicado: (2015)

Poxvirus immunotherapies in combination with immune checkpoint inhibitors synergize to eliminate tumors in a mouse tumor model
por: Foy, Susan P, et al.
Publicado: (2013)

Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4(+)CD45RO(+)CD25(+)CD127(low) regulatory T cells
por: Walter, Gina J, et al.
Publicado: (2012)

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM)
por: Kim, Dae Won, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uufc6qqs168gt3p40ejbrki5p7